CMS Removes the Main Medicare Brake on Symptomatic TAVR

Medicare’s biggest coverage hurdle for symptomatic TAVR is gone, opening access for approved systems while raising the bar on center performance.

Updated

What is this trend?

CMS has lifted the main Medicare coverage barrier for symptomatic severe aortic stenosis treated with FDA-approved complete TAVR systems, expanding access while keeping strict procedural and volume requirements.

  • Medicare no longer requires CED for symptomatic TAVR with approved complete valve systems.
  • Asymptomatic severe aortic stenosis remains under CED, limiting the broader market.
  • CMS tightened heart-team, assessment, and volume standards, favoring high-capacity centers.
  • Demand should shift toward PMA-backed end-to-end TAVR platforms and procedural tools.
  • Access is expanding, but execution and reimbursement compliance now decide share.

What’s the latest?

CMS this week removed Coverage with Evidence Development for TAVR in symptomatic severe aortic stenosis when performed under an FDA-approved indication using a complete valve and implantation system w

Regulated AI Workflow Expansion, Platform Consolidation, and CMS Easing on TAVR

How it developed

  1. Compliance, reimbursement, and localization are reshaping medtech competition
    • Outpatient Workflow and Infection Control Are Reallocating Device Demand

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Medical Devices & Tools

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.